Harvard Bioscience Inc. has announced a CEO succession plan, with current Board member John Duke set to become President & CEO following the planned retirement of Jim Green, effective July 28, 2025. Jim Green is retiring after over 8 years as Chairman and 6 years as President & CEO. Additionally, Rob Gagnon and Seth Benson have been appointed as new independent Board members. The company anticipates Q2 2025 revenue of $20.4 million and maintains its previously announced gross margin guidance.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。